Attached files
file | filename |
---|---|
EX-99.1 - Eloxx Pharmaceuticals, Inc. | v208729_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): January 24,
2011
Senesco Technologies,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
001-31326 | 84-1368850 |
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
303
George Street, Suite 420, New Brunswick, New
Jersey
|
08901
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(732) 296-8400
|
(Registrant's
telephone number,
including
area code)
|
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
|
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
Item
8.01 Other
Events.
Senesco
Technologies, Inc. (the “Company”) announced today that the Company has filed an
Investigational New Drug application with the U.S. Food and Drug Administration
for the Company’s lead drug candidate, SNS01-T, for the treatment of multiple
myeloma. The full text of the press release is attached to this current report
on Form 8-K as Exhibit 99.1.
Item
9.01. Financial Statements and
Exhibits.
(d) Exhibits.
Exhibit No.
|
Description
|
99.1
|
Press
Release of Senesco Technologies, Inc. dated
January
24,
2011.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
SENESCO
TECHNOLOGIES, INC.
|
|
Dated:
January 24, 2011
|
By: /s/ Leslie J. Browne,
Ph.D.
|
Name:
Leslie J. Browne, Ph.D.
|
|
Title: President
and Chief Executive
Officer
|